Research programme: anti-infectives - Athelas

Drug Profile

Research programme: anti-infectives - Athelas

Alternative Names: ATH 18534

Latest Information Update: 19 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Athelas
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 21 Aug 2006 Athelas has been acquired by MerLion Pharmaceuticals
  • 08 Feb 2006 A drug discovery and research collaboration between Athelas and MerLion Pharmaceuticals has concluded
  • 08 Feb 2006 Discontinued - Preclinical for Bacterial infections in Singapore (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top